149 related articles for article (PubMed ID: 24133973)
1. [Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].
Ding JF; Zhong DF
Yao Xue Xue Bao; 2013 Jul; 48(7):1080-90. PubMed ID: 24133973
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of tyrosine kinase inhibitors.
van Erp NP; Gelderblom H; Guchelaar HJ
Cancer Treat Rev; 2009 Dec; 35(8):692-706. PubMed ID: 19733976
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
Di Gion P; Kanefendt F; Lindauer A; Scheffler M; Doroshyenko O; Fuhr U; Wolf J; Jaehde U
Clin Pharmacokinet; 2011 Sep; 50(9):551-603. PubMed ID: 21827214
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
Erdem L; Giovannetti E; Leon LG; Honeywell R; Peters GJ
Curr Top Med Chem; 2012; 12(15):1649-59. PubMed ID: 22978339
[TBL] [Abstract][Full Text] [Related]
5. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib.
Tang SC; de Vries N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
J Pharmacol Exp Ther; 2013 Sep; 346(3):486-94. PubMed ID: 23843632
[TBL] [Abstract][Full Text] [Related]
6. PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors.
Harmsen S; Meijerman I; Maas-Bakker RF; Beijnen JH; Schellens JH
Eur J Pharm Sci; 2013 Mar; 48(4-5):644-9. PubMed ID: 23277288
[TBL] [Abstract][Full Text] [Related]
7. BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib.
Huang WC; Hsieh YL; Hung CM; Chien PH; Chien YF; Chen LC; Tu CY; Chen CH; Hsu SC; Lin YM; Chen YJ
PLoS One; 2013; 8(12):e83627. PubMed ID: 24391798
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.
Scheffler M; Di Gion P; Doroshyenko O; Wolf J; Fuhr U
Clin Pharmacokinet; 2011 Jun; 50(6):371-403. PubMed ID: 21553932
[TBL] [Abstract][Full Text] [Related]
9. The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.
Heine A; Schilling J; Grünwald B; Krüger A; Gevensleben H; Held SA; Garbi N; Kurts C; Brossart P; Knolle P; Diehl L; Höchst B
Cancer Immunol Immunother; 2016 Mar; 65(3):273-82. PubMed ID: 26786874
[TBL] [Abstract][Full Text] [Related]
10. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
Lankheet NA; Knapen LM; Schellens JH; Beijnen JH; Steeghs N; Huitema AD
Ther Drug Monit; 2014 Jun; 36(3):326-34. PubMed ID: 24305627
[TBL] [Abstract][Full Text] [Related]
11. Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.
Hu S; Niu H; Minkin P; Orwick S; Shimada A; Inaba H; Dahl GV; Rubnitz J; Baker SD
Mol Cancer Ther; 2008 May; 7(5):1110-20. PubMed ID: 18483300
[TBL] [Abstract][Full Text] [Related]
12. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
[TBL] [Abstract][Full Text] [Related]
13. Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib.
Tlemsani C; Huillard O; Arrondeau J; Boudou-Rouquette P; Cessot A; Blanchet B; Thomas-Schoemann A; Coriat R; Durand JP; Giroux J; Alexandre J; Goldwasser F
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):785-94. PubMed ID: 25809423
[TBL] [Abstract][Full Text] [Related]
14. Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells.
Elsner A; Lange F; Fitzner B; Heuschkel M; Krause BJ; Jaster R
World J Gastroenterol; 2014 Jun; 20(24):7914-25. PubMed ID: 24976727
[TBL] [Abstract][Full Text] [Related]
15. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.
Li J; Cusatis G; Brahmer J; Sparreboom A; Robey RW; Bates SE; Hidalgo M; Baker SD
Cancer Biol Ther; 2007 Mar; 6(3):432-8. PubMed ID: 17312388
[TBL] [Abstract][Full Text] [Related]
16. Effect of 5,7-dimethoxyflavone on Bcrp1-mediated transport of sorafenib in vitro and in vivo in mice.
Bae S; D'Cunha R; Shao J; An G
Eur J Pharm Sci; 2018 May; 117():27-34. PubMed ID: 29425861
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L
Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911
[TBL] [Abstract][Full Text] [Related]
18. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.
Hu S; Chen Z; Franke R; Orwick S; Zhao M; Rudek MA; Sparreboom A; Baker SD
Clin Cancer Res; 2009 Oct; 15(19):6062-9. PubMed ID: 19773380
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bullet.
Pander J; Guchelaar HJ; Gelderblom H
Curr Opin Mol Ther; 2010 Dec; 12(6):654-61. PubMed ID: 21154157
[TBL] [Abstract][Full Text] [Related]
20. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.
D'Cunha R; Bae S; Murry DJ; An G
Biopharm Drug Dispos; 2016 Oct; 37(7):397-408. PubMed ID: 27418107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
